News

Lysogene’s MPS IIIA gene therapy program recently failed its primary endpoint in the phase 2/3 AAVANCE trial.

The FDA has decided not to hold an advisory committee meeting for Roctavian after all.

CB-010 most recently demonstrated a 100% complete response rate in data presented at the EHA 2022 congress.

BEAM-101 is edited with a next-generation CRIPSR product to mimic single nucleotide polymorphisms that enable persistence of fetal hemoglobin.

In preclinical research, TN-401 was shown to significantly increase the lifespan of PKP2-knock-out mice.

SRP-9001's PDUFA date is set for May 23, 2023.

Review top news and interview highlights from the week ending November 25, 2022.

The first participant has been followed-up for 3 months so far after treatment while the second is only 1 week post-treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The IND clearance comes after Legend terminated another clinical trial in T-cell lymphoma in July 2022.

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

The phase 1 clinical trial plans to initiate enrollment in early 2023.

SRD-001 is designed to increase expression and functional activity of SERCA2a, down-regulation of which is associated with all forms of heart failure.

Updated data from the SPEARHEAD-1 study were presented at the 2022 CTOS Annual Meeting.

The FDA has requested supplemental validation information and comparability data for the tumor-infiltrating therapy.

Review top news and interview highlights from the week ending November 18, 2022.

The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.

Editas has paused enrollment in the BRILLIANCE trial after efficacy was only seen in a very small subset of patients.

CAN-2409 transduces tumor cells with the thymidine kinase gene, sensitizes these cells to valacyclovir, and stimulates patients’ immune response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Updated data from a first-in-human trial were presented at the SITC 2022 meeting.

The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.

4D Molecular Therapeutics plans to initiate enrollment in the phase 2 randomized portion of the study in the first quarter of 2023.

KYV-101 is an autologous version of a CD19-directed fully human CAR-T construct.

The first 3 patients dosed have been attack-free for up to 10.5 months.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

A2B530 and A2B694 target CEA and MSLN cells that have HLA loss of heterozygosity.

Review top news and interview highlights from the week ending November 11, 2022.